Home › Funds › Eversept Partners, LP › VRDN

Eversept Partners, LP position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Eversept Partners, LP reported holding 831,142 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$15.3M, representing 0.80% of its reported portfolio and ranking #34 among its reported holdings. Eversept Partners, LP has disclosed VRDN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)831.14K sh
Reported value held$15.27M
Portfolio Weight0.80%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Eversept Partners, LP's VRDN position evolved

Eversept Partners, LP first disclosed a stake in VRDN in Q3 2023 at 443,270 shares (US$6.8M). The position peaked in Q4 2025 at 1,782,235 shares, worth US$55.5M. Across 12 filings, Eversept Partners, LP increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 831,142 shares valued at US$15.3M — an increase of 117,873 shares quarter over quarter.. Notable position changes include a 69% trim in Q4 2023 (shares fell 20% over the following quarter), a 299% increase in Q2 2024 (shares rose 75% over the following quarter), a 77% increase in Q1 2025 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 443.27K $6.80M New
Q4 2023 137.34K $2.99M Reduce
Q1 2024 142.07K $2.49M Add
Q2 2024 567.49K $7.38M Add
Q3 2024 691.23K $15.73M Add
Q4 2024 780.00K $14.95M Add
Q1 2025 1.38M $18.57M Add
Q2 2025 1.90M $26.60M Add
Q3 2025 1.92M $41.53M Add
Q4 2025 1.78M $55.46M Reduce
Q1 2026 713.27K $13.95M Reduce
Q2 2026 831.14K $15.27M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 37 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Eversept Partners, LP held VRDN?

Eversept Partners, LP has disclosed VRDN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Eversept Partners, LP's current position in VRDN?

As of Q2 2026, Eversept Partners, LP holds 831.14K shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $15.27M, representing 0.80% of its reported portfolio and ranking #34.

Has Eversept Partners, LP been buying or selling VRDN?

In the latest 13F filing (Q2 2026), Eversept Partners, LP increased its position in VRDN. The position peaked in Q4 2025 at 1.78M shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.